Orchid Pharma Ltd

Orchid Pharma Limited has announced that its Board of Directors will convene on October 20, 2026. The primary agenda item is to consider and evaluate various strategic options for raising capital. These options include issuing equity shares, convertible debentures, or warrants, potentially through qualified institutions placement, preferential issue, private placement, or a public issue of equity and/or debt securities. The company will also explore any other permissible modes of fundraising, subject to necessary regulatory and member approvals.

Orchid Pharma Ltd has announced the closure of its trading window for the second quarter of the financial year 2026-27, which ends on September 30, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from October 1, 2026, until 48 hours after the declaration of the unaudited financial results (standalone and consolidated) for the aforementioned quarter. The specific date for the Board of Directors' meeting to approve these results will be communicated separately. All individuals in possession of unpublished price-sensitive information are prohibited from trading in the company's securities during this period.

Orchid Pharma Ltd has announced the successful listing and admission to dealings of 4,45,86,052 equity shares on the National Stock Exchange (NSE) and BSE Limited. These shares were issued and allotted pursuant to the Scheme of Amalgamation sanctioned by the Hon'ble National Company Law Tribunal, Chennai Bench. The trading of these new equity shares commenced effective September 23, 2026. This development marks a significant step following the company's earlier intimation on August 01, 2026, regarding the allotment.

Orchid Pharma Ltd has purchased a property that was previously under a lease arrangement with DBS Bank India Limited. This acquisition signifies the permanent closure of the company's arrangement with DBS Bank concerning the property, resolving a dispute related to lease rentals and establishing clear ownership for Orchid Pharma. The transaction brings certainty and finality to the company's property holdings.

Orchid Pharma Limited announced that its Whole Time Director, Mr. Mridul Dhanuka, will participate in an investor roadshow in Mumbai. The physical group meetings are scheduled for September 28, 29, and 30, 2026. The company stated that the schedule might change due to unforeseen circumstances. Importantly, no Unpublished Price Sensitive Information (UPSI) will be shared during these investor interactions.

Orchid Pharma Ltd has filed its Annual Report for the Financial Year 2025-26, which includes the Notice for its 33rd Annual General Meeting (AGM). The AGM is scheduled for September 29, 2026, at 12:00 PM IST, to be conducted via Video Conferencing/Other Audio Visual Means. The report details the company's financial highlights, statutory reports, and financial statements, including standalone and consolidated figures. It also contains a 'Safe Harbour' statement regarding forward-looking statements and discusses the amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited. The Annual Report and AGM notice are available on the company's website.

Orchid Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as mandated by SEBI regulations. The report, which is part of the company's Annual Report, details its operations, employee data, and market reach. Key disclosures include the company's primary business activity of manufacturing and sales of Active Pharmaceutical Ingredients (APIs) and products, accounting for 97% of its turnover. The report also outlines the company's operational footprint with 6 plants and 3 offices nationally, serving 15 states and 52 countries internationally, with exports contributing 64.55% to total turnover. Employee statistics and sustainability initiatives are also covered.

Orchid Pharma Ltd announced key decisions from its Board of Directors meeting held on September 03, 2026. The company appointed M/s. J Karthikeyan & Associates as its Cost Auditors for the Financial Year 2026-27. Additionally, Mr. Arjun Dhanuka's designation was changed to Whole-Time Director, effective from September 03, 2026, for a term of five years. The board also approved the notice for the 33rd Annual General Meeting scheduled for September 29, 2026, setting cut-off dates for AGM notice eligibility and e-voting.

Orchid Pharma Ltd's Board of Directors convened on September 03, 2026, approving key appointments and strategic decisions. The board appointed Mr. Arjun Dhanuka as Whole-Time Director for a five-year term and M/s. J Karthikeyan & Associates as Cost Auditors for FY 2026-27, subject to member ratification. Additionally, the company announced the 33rd Annual General Meeting scheduled for September 29, 2026, with September 04, 2026, set as the cut-off date for AGM notice eligibility and September 22, 2026, for e-voting eligibility. The remote e-voting period will run from September 26 to September 28, 2026.

Orchid Pharma Ltd has filed a Statement of Deviation or Variation for the quarter ended June 30, 2026, regarding the use of proceeds from its Qualified Institutional Placement (QIP). The company raised ₹400 Crores on June 27, 2023. A deviation in fund utilization was noted and approved by shareholders on September 20, 2025. The modification in allocation is due to changes in the business environment and strategic requirements, leading to the postponement of the 'new block at API Facility' project. Proceeds originally allocated to this project have been reallocated to mitigate financial burdens and ensure optimal utilization. The Audit Committee has reviewed the statement.